Table 2.
Characteristics of patients with body mass index ≥27 or <27 kg/m2
| BMI ≥27 kg/m2 (n = 170) |
BMI <27 kg/m2 (n = 263) |
p Value |
|
|---|---|---|---|
| Age (years) | 56 ± 10 | 57 ± 11 | 0.381 |
| Men | 119 (70.0%) | 199 (75.7%) | 0.192 |
| AF duration (years) | 6.2 ± 6.2 | 6.5 ± 6.0 | 0.563 |
| Nonparoxysmal AF | 63 (37.1%) | 55 (20.9%) | <0.001 |
| Type 2 diabetes mellitus | 20 (11.8%) | 26 (9.9%) | 0.536 |
| Hypertension | 101 (59.4%) | 103 (39.2%) | <0.001 |
| Heart failure | 11 (6.5%) | 12 (4.6%) | 0.387 |
| Previous embolic events | 9 (5.3%) | 18 (6.8%) | 0.515 |
| CHADS2 | <0.001 | ||
| 0 | 54 (31.8%) | 135 (51.3%) | |
| 1 | 85 (50.0%) | 83 (31.6%) | |
| ≥2 | 31 (18.2%) | 45 (17.1%) | |
| Coronary artery disease | 17 (10.0%) | 18 (6.8%) | 0.239 |
| LA size (mm) | 40.9 ± 5.9 | 36.9 ± 6.1 | <0.001 |
| LA size/body surface area (mm/m2) | 21.6 ± 3.3 | 21.4 ± 3.6 | 0.536 |
| Left ventricular end-diastolic diameter (mm) | 49.5 ± 6.3 | 47.9 ± 5.2 | 0.040 |
| Left ventricular end-diastolic diameter/body surface area (mm/m2) | 26.2 ± 3.5 | 27.8 ± 3.2 | <0.001 |
| Left ventricular end-systolic diameter (mm) | 32.6 ±6.1 | 31.0 ± 5.3 | 0.040 |
| Left ventricular end-systolic diameter/body surface area (mm/m2) | 17.3 ± 3.3 | 18.0 ± 3.0 | 0.027 |
| Ejection fraction (%) | 63.2 ± 8.8 | 63.7 ± 8.4 | 0.547 |
| BMI (kg/m2) | 29.4 ± 2.0 | 24.0 ± 2.0 | <0.001 |
| Creatinine (μmol/L) | 77.4 ± 18.9 | 75.2 ± 19.7 | 0.247 |
| Fibrinogen (g/L) | 2.74 ± 0.67 | 2.58 ± 0.51 | 0.008 |
| Warfarin | 5 (2.9%) | 7 (2.7%) | 0.863 |
| Aspirin | 30 (17.6%) | 35 (13.3%) | 0.217 |
| Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers | 61 (35.9%) | 62 (23.6%) | 0.006 |
| Statins | 9 (5.3%) | 19 (7.2%) | 0.549 |
| Thrombus | 18 (10.6%) | 8 (3.0%) | 0.001 |